ClinicalTrials.gg
CompletedNCT01364649Updated Oct 9, 2014Results posted

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

A Phase 3 interventional study of Vortioxetine and Escitalopram in Treatment Outcome, sponsored by Takeda. Completed at 62 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
447
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Sexual Dysfunction, Physiological with a site in United States — 16 open to participants now, 17 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.

Enrollment
9th of 107
447 · median 60
Started
2011
with 8 others
Phase 3
16 of 127
none open now
Registered
46th of 127
by date

Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 9th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2011, is one of 16 in phase 3, and was the 46th registered.

Sexual Dysfunction, Physiological

385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.

Browse Sexual Dysfunction, Physiological studies →

Open to participants now

16 of the 127 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Sexual Dysfunction, Physiological studies recruiting now, 23 (50%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Sexual Dysfunction, Physiological with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.

Read the detailed description

The drug being tested in this study is called Lu AA21004. Lu AA21004 is being tested to treat people who have major depressive disorder (MDD). This study will look at sexual function in people who take Lu AA21004.

The study will enroll approximately 440 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Lu AA21004 10 to 20 mg
  • Escitalopram 10 to 20 mg - This is a comparator drug that is also used to treat MDD.

All participants will be asked to take one tablet at the same time each day throughout the study. All participants will be asked to answer questionnaires at each study visit.

This multi-centre trial will be conducted in the United States and Canada. The overall time to participate in this study is 14 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone 21 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Treatment Outcome

Keywords

  • Sexual Dysfunction, Physiological
  • Depressive Disorder, Major
  • Depression
  • Antidepressive Agents
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a man or a woman aged between 18 and 55 years, inclusive, who is currently being treated with selective serotonin reuptake inhibitor (SSRI) monotherapy (only citalopram, paroxetine, or sertraline allowed) for at least 8 weeks, which was prescribed to treat a major depressive episode (MDE), according to the criteria.
  2. Is currently stable; and has a Clinical Global Impression Scale-Severity of Illness Scale (CGI-S) score of ≤3.
  3. Is currently experiencing treatment-emergent sexual dysfunction (TESD; defined as a Changes in Sexual Functioning Questionnaire (CSFQ-14) total score ≤41 for women and ≤47 for men), considered to be attributable to the current SSRI monotherapy and is suitable for a switch.

Exclusion criteria

Exclusion Criteria:

  1. Has previously participated in a Lu AA21004 clinical study.
  2. Has 1 or more the following: any current psychiatric disorder other than MDD as defined in the , Fourth Edition, Text Revision (DSM-IV-TR; as assessed by the Mini International Neuropsychiatric Interview Version 6.0.0); current or history of manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR; current diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in sustained full remission for at least 2 years prior to Screening (subject must also have negative urine drug screen prior to Baseline); presence or history of a neurological disorder (including epilepsy); neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc); or any Axis II disorder that might compromise the study.
  3. Has sexual dysfunction associated with an etiology other than SSRI treatment or current MDE (e.g., due to a medical condition, such as diabetes or hypertension, a medication, a genital anatomical deformity, or alcohol abuse).
  4. Is nonsexually active or anticipates decreasing frequency of sexual activity (ie, sexual activity anticipated to lead to orgasm or that would normally lead to orgasm, which can include sexual intercourse, oral sex, masturbation, sexual fantasies, and/or thinking of sexual activity) during the course of the study below the level at study initiation.
  5. Is a male with a history of premature ejaculation in the past year.
  6. Has had major relationship changes during the preceding SSRI treatment period or plans to have major relationship changes during the course of the study.
  7. Has a sexual partner(s) who plans to initiate treatment for sexual dysfunction during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
447 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.

    Drug: Vortioxetine · Drug: Placebo

  • Active comparator
    Escitalopram

    Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.

    Drug: Escitalopram

Interventions

  • Vortioxetine tablets

    Also known as: Lu AA21004

  • Escitalopram tablets

    Also known as: Lexapro

  • DrugPlacebo

    Vortioxetine Placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8

    The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed

    The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  2. Number of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed

    The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. Normal sexual functioning is defined as a CSFQ-14 total score of \>41 for women and \>47 for men. Abnormal sexual functioning is defined as a CSFQ-14 total score of ≤41 for women and ≤47 for men. All subjects entered the study with abnormal sexual functioning. A shift to normal indicates that symptoms have improved.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8

07

Results

Posted Oct 9, 2014

Participant flow

Participants took part in the study at 57 sites in the US and 9 sites in Canada from 16 June 12011 to 9 December 2013.

Participant flow — Overall Study
MilestoneVortioxetineEscitalopram
Started225222
Completed169179
Not completed5643
Withdrew: Pretreatment event or adverse event2014
Withdrew: Lack of efficacy60
Withdrew: Non-compliance with investigational drug10
Withdrew: Protocol deviations48
Withdrew: Withdrawal of consent97
Withdrew: Lost to follow-up1213
Withdrew: Other41

Outcome measures

PrimaryChange From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8

The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8
scores on a scaleVortioxetineEscitalopram
Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 88.8 ± 0.646.6 ± 0.64
Statistical analysis
  • Vortioxetine vs Escitalopram · Mixed Model Repeated Measurements · p = 0.013 · Ls mean difference: 2.2 · 95% CI 0.48 to 4.02The primary analysis was performed by using observed case data only.
SecondaryChange From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed

The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix.

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed
scores on a scaleVortioxetineEscitalopram
Week 1 (n=213, 206)2.5 ± 0.392.2 ± 0.40
Week 2 (n=203, 200)4.9 ± 0.463.7 ± 0.47
Week 4 (n=187, 188)7.0 ± 0.554.8 ± 0.55
Week 6 (n=175, 176)8.0 ± 0.596.4 ± 0.60
SecondaryNumber of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed

The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. Normal sexual functioning is defined as a CSFQ-14 total score of \>41 for women and \>47 for men. Abnormal sexual functioning is defined as a CSFQ-14 total score of ≤41 for women and ≤47 for men. All subjects entered the study with abnormal sexual functioning. A shift to normal indicates that symptoms have improved.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8
Reported as:
Number · number of participants
Number of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed
number of participantsVortioxetineEscitalopram
Week 1 (n=213, 205)4836
Week 2 (n=217, 206)8163
Week 4 (n=217, 206)9384
Week 6 (n=217, 206)11293
Week 8 (n=217, 206)11391

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug (Up to 12 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine—3/224 (1.3%)90/224 (40.2%)
Escitalopram—1/221 (0.5%)60/221 (27.1%)
Most frequent serious events
Most frequent serious events
EventVortioxetineEscitalopram
DepressionPsychiatric disorders2/2240/221
Mesenteric vein thrombosisGastrointestinal disorders0/2241/221
Angina pectorisCardiac disorders1/2240/221
AnxietyPsychiatric disorders1/2240/221
NephrolithiasisRenal and urinary disorders1/2240/221
Most frequent other events
Most frequent other events
EventVortioxetineEscitalopram
NauseaGastrointestinal disorders56/22412/221
HeadacheNervous system disorders21/22417/221
DizzinessNervous system disorders18/22411/221
IrritabilityGeneral disorders11/22416/221
Pruritus generalisedSkin and subcutaneous tissue disorders13/2240/221
FatigueGeneral disorders10/22412/221
AnxietyPsychiatric disorders4/22412/221

Baseline characteristics

All randomized set (N=447): All study participants who were screened and randomized to one of two treatment arms.

Age, Continuous
Age, Continuous(years)VortioxetineEscitalopramTotal
Mean39.3 ± 9.9640.2 ± 10.0139.8 ± 9.98
Age, Customized
Age, Customized(participants)VortioxetineEscitalopramTotal
≤41 years122112234
>41 years103110213
Sex: Female, Male
Sex: Female, Male(Participants)VortioxetineEscitalopramTotal
Female128135263
Male9787184
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)VortioxetineEscitalopramTotal
Hispanic or Latino143650
Non-Hispanic and Non-Latino211186397
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)VortioxetineEscitalopramTotal
Caucasian (or White, including Hispanic)178181359
Black of African American413576
Asian437
American Indian or Alaska Native134
Native Hawaiian or Other Pacific Islander101
Region of Enrollment
Region of Enrollment(participants)VortioxetineEscitalopramTotal
North America225222447
Height
Height(cm)VortioxetineEscitalopramTotal
Mean169.6 ± 9.73170.3 ± 8.81169.9 ± 9.28
Weight
Weight(kg)VortioxetineEscitalopramTotal
Mean79.62 ± 16.20281.22 ± 16.01280.41 ± 16.110

8 further baseline measures are reported on the registry.

08

Study locations

62 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Chino, California, United States
  • Costa Mesa, California, United States
  • Encino, California, United States
  • Escondido, California, United States
  • Irvine, California, United States
  • Newport Beach, California, United States
  • Oceanside, California, United States
  • San Diego, California, United States
  • Norwich, Connecticut, United States
  • Washington, District of Columbia, United States
  • Coral Springs, Florida, United States
  • Fort Myers, Florida, United States
  • Gainesville, Florida, United States
  • Jacksonville, Florida, United States
  • Lauderhill, Florida, United States
  • North Miami, Florida, United States
  • Orlando, Florida, United States
  • Sanford, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Joliet, Illinois, United States
  • Lake Charles, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Gaithersburg, Maryland, United States
  • Towson, Maryland, United States
  • Boston, Massachusetts, United States
  • Weymouth, Massachusetts, United States
  • Flowood, Mississippi, United States
  • Creve Coeur, Missouri, United States
  • St. Louis, Missouri, United States
  • Toms River, New Jersey, United States
  • Willingboro, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Staten Island, New York, United States
  • Cincinatti, Ohio, United States
  • Dayton, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Allentown, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Charlottesville, Virginia, United States
  • Seattle, Washington, United States
  • Waukesha, Wisconsin, United States
  • Medicine Hat, Alberta, Canada
  • Kelowna, British Columbia, Canada
  • Penticton, British Columbia, Canada
  • Sydney, Nova Scotia, Canada
  • Burlington, Ontario, Canada
  • Chatham, Ontario, Canada
  • Kingston, Ontario, Canada
  • Mississauga, Ontario, Canada
  • Toronto, Ontario, Canada
09

References and documents

Publications

  • Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr. 2020 Feb;25(1):50-63. doi: 10.1017/S1092852919000750. PubMed 31010445 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 2, 2011
Start
Jun 2011
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Oct 9, 2014
Last update
Oct 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01364649
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 2, 2011
Start date
Jun 2011
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Oct 9, 2014
Last update
Oct 9, 2014

Study contacts

Senior Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion